Switch theme
Sign up to access all valuation multiples
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
2009
710
LTM Revenue $804M
LTM EBITDA -$137M
$2.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Apellis Pharmaceuticals has a last 12-month revenue of $804M and a last 12-month EBITDA of -$137M.
In the most recent fiscal year, Apellis Pharmaceuticals achieved revenue of $781M and an EBITDA of -$155M.
Apellis Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Apellis Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $397M | $781M | XXX | XXX | XXX |
| Gross Profit | $69.8M | $338M | XXX | XXX | XXX |
| Gross Margin | 18% | 43% | XXX | XXX | XXX |
| EBITDA | -$495M | -$155M | XXX | XXX | XXX |
| EBITDA Margin | -125% | -20% | XXX | XXX | XXX |
| Net Profit | -$652M | -$529M | XXX | XXX | XXX |
| Net Margin | -164% | -68% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Apellis Pharmaceuticals's stock price is $19.
Apellis Pharmaceuticals has current market cap of $2.4B, and EV of $2.5B.
See Apellis Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.5B | $2.4B | XXX | XXX | XXX | XXX | $-1.43 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Apellis Pharmaceuticals has market cap of $2.4B and EV of $2.5B.
Apellis Pharmaceuticals's trades at 3.1x LTM EV/Revenue multiple, and -18.2x LTM EBITDA.
Analysts estimate Apellis Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Apellis Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.5B | XXX | XXX | XXX |
| EV/Revenue | 3.2x | XXX | XXX | XXX |
| EV/EBITDA | -16.1x | XXX | XXX | XXX |
| P/E | -12.3x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -28.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpApellis Pharmaceuticals's NTM/LTM revenue growth is 13%
Apellis Pharmaceuticals's revenue per employee for the last fiscal year averaged $1.1M, while opex per employee averaged $1.2M for the same period.
Over next 12 months, Apellis Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Apellis Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Apellis Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 97% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -20% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -69% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -7% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 42% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 106% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Apellis Pharmaceuticals acquired XXX companies to date.
Last acquisition by Apellis Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Apellis Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Apellis Pharmaceuticals founded? | Apellis Pharmaceuticals was founded in 2009. |
| Where is Apellis Pharmaceuticals headquartered? | Apellis Pharmaceuticals is headquartered in United States of America. |
| How many employees does Apellis Pharmaceuticals have? | As of today, Apellis Pharmaceuticals has 710 employees. |
| Who is the CEO of Apellis Pharmaceuticals? | Apellis Pharmaceuticals's CEO is Dr. Cedric Francois, M.D.. |
| Is Apellis Pharmaceuticals publicy listed? | Yes, Apellis Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Apellis Pharmaceuticals? | Apellis Pharmaceuticals trades under APLS ticker. |
| When did Apellis Pharmaceuticals go public? | Apellis Pharmaceuticals went public in 2017. |
| Who are competitors of Apellis Pharmaceuticals? | Similar companies to Apellis Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Apellis Pharmaceuticals? | Apellis Pharmaceuticals's current market cap is $2.4B |
| What is the current revenue of Apellis Pharmaceuticals? | Apellis Pharmaceuticals's last 12-month revenue is $804M. |
| What is the current EBITDA of Apellis Pharmaceuticals? | Apellis Pharmaceuticals's last 12-month EBITDA is -$137M. |
| What is the current EV/Revenue multiple of Apellis Pharmaceuticals? | Current revenue multiple of Apellis Pharmaceuticals is 3.1x. |
| What is the current EV/EBITDA multiple of Apellis Pharmaceuticals? | Current EBITDA multiple of Apellis Pharmaceuticals is -18.2x. |
| What is the current revenue growth of Apellis Pharmaceuticals? | Apellis Pharmaceuticals revenue growth between 2023 and 2024 was 97%. |
| Is Apellis Pharmaceuticals profitable? | Yes, Apellis Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
